Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of ONTAK [denileukin diftitox] with Metastatic Melanoma.

Trial Profile

Phase II Trial of ONTAK [denileukin diftitox] with Metastatic Melanoma.

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 06 Aug 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Sep 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top